The 8th CAR-TCR Summit Europe: Your European Hub of Next Generation Cell Therapy Innovation
Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources. This, along with the recent investments in Enara Bio, ArsenalBio, Kyverna and Artiva signifies that the field is poised to regain momentum.
It’s not just investments that are gaining traction. Recent approvals are changing the game, with Iovance and Adaptimmune making strides in treating solid tumours, Kite securing first-line treatment approval, and donor cell therapies, demonstrating success in putting autoimmune diseases into remission. The industry is brimming with new hope!
The 8th CAR-TCR Summit Europe returns to London this February as your must-attend forum to remain on the pulse of recent innovation in cell therapy. Join us to collaborate, innovate, and overcome the shared challenges of safety concerns, high cost of goods, effective tumour targeting, and more. Let’s work together to drive success in clinical trials, secure regulatory approvals, and position cell therapy as the first-line treatment for oncological and non-oncological indications.
What's New for 2025?
Autoimmune Focus Day
Cabaletta Bio, GentiBio and Cullinan Therapeutics are leading the charge in autoimmune indications. Join them to benchmark your approaches, and ask your pressing questions on choosing disease targets, navigating safety concerns, and improving durablity of response to capitalise on the future of cell therapy
Regulatory Focus Day
Ensure IND and BLA approval processes don't delay your path to commercialisation. Join Sana Biotech, Adicet Bio, Korecyte, and more to hear about successful regulatory strategies and approaches to engage with regulators collaboratively to streamline your approach
Refreshed Content Tracks
We've meticulously researched with subject matter experts to identify the key challenges faced by the industry. This year, the programme spans Discovery, Clinical Development and CMC, Process & Analytics to ensure specifically curated content to each stage of development
Top Speakers
"It will be great to re-connect with the community and to see advances on the different avenues of CAR/TCR based therapy"
Zelluna Immunotherapy, 2025 Speaker
Brand New Presenting Companies for 2025
"I’m looking forward to engaging with investors and partners to accelerate our path to IND and approval"
NKILT Therapeutics, 2025 Speaker